echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > One-time drug suppression of HIV for up to six months, Elite Neutralizing Antibody Phase 1 Trial Published

    One-time drug suppression of HIV for up to six months, Elite Neutralizing Antibody Phase 1 Trial Published

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Currently, more than 35 million people worldwide are infected with HIV (HIV), and there are nearly 2 million new cases each year.


    HIV-1 specific broad-spectrum neutralizing monoclonal antibody targeting HIV-1 envelope protein is one of the treatments under investigation for the treatment and prevention of HIV infection


    One of the antibodies under investigation, named PGT121, was isolated from an African donor infected with HIV-1 subtype A.


    This research comes from Beth Israel Deaconess Medical Center (BethIsrael Deaconess Medical Center)


    Next, the research team evaluated antiviral activity in 13 HIV-infected people who did not receive ART therapy


    After a single dose of antibody was injected, among the 9 people with a high baseline viral load, the viral load continued to decline for 7-10 days, and then rebounded to the baseline level on the 28th day


    Dr.


    Consistent with previous studies on anti-HIV antibody therapy, in this trial, researchers also observed that 12 of 13 subjects developed partial resistance to the antibody-HIV is rapidly responding to drug therapies and vaccine strategies The ability to develop resistance is one of the reasons the virus is so difficult to eradicate


    "All in all, (this) antibody therapy is safe, well tolerated, and has a rapid antiviral effect on HIV-1 infected persons with a detectable viral load


    Reference

    [1] Kathryn E.


    [2]'Elite neutralizing' antibody demonstrates long-term viral suppression in persons living with HIV in phase 1 trial.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.